Angiotensin II type-1 receptor blockers (ARBs) are regarded as first-line treatments for type-2 diabetes with hypertension. Despite the availability of various types of ARBs, there are no comparative studies of their effects on patients with diabetes. In this open-label prospective crossover study, we compared the effects of olmesartan (20 mg/day) and telmisartan (40 mg/day). Twenty Japanese early-stage type-2 diabetes patients with hypertension treated with valsartan (80 mg/day) for at least 8 weeks were recruited to this study. At study entry, valsartan was changed to olmesartan (20 mg/day) or telmisartan (40 mg/day) and administered for 8 weeks. The drugs were then switched and treatment was continued for another 8 weeks. We analyzed the blood pressure lowering effects of each drug by 24-h ambulatory blood pressure monitoring at 0, 8, and 16 weeks. Simultaneously, we measured metabolic parameters and inflammation markers. Olmesartan lowered mean systolic and diastolic blood pressure more significantly than did telmisartan. While there were no differences between the groups in metabolic parameters, including HbA1c and adiponectin, the decreases in serum interleukin-6 and highly sensitive C-reactive protein were more significant by olmesartan treatment. Our results indicate that olmesartan has more potent arterial blood pressure lowering and anti-inflammatory effects than telmisartan. (Hypertens Res 2008; 31: 7−13)
Hypertension in Diabetes Study (HDS) : I. Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications. J Hypertens 1993; 11: 309–317.
Hansson L, Zanchetti A, Carruthers SG, et al, HOT Study Group : Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755–1762.
UK Prospective Diabetes Study Group : Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703–713.
Chobanian AV, Bakris GL, Black HR, et al : The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560–2572.
Japanese Society of Hypertension : Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2004). Hypertens Res 2006; 29 ( Suppl): S1–S105.
Hirose H, Saito I : Trends in blood pressure control in hypertensive patients with diabetes mellitus in Japan. Hypertens Res 2003; 26: 717–722.
Dzau VJ : Theodore Cooper Lecture: tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis. Hypertension 2001; 37: 1047–1052.
Zhang C, Hein TW, Wang W, Kuo L : Divergent roles of angiotensin II AT1 and AT2 receptors in modulating coronary microvascular function. Circ Res 2003; 92: 322–329.
Pfeffer MA, Swedberg K, Granger CB, et al : Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003; 362: 759–766.
Dahlof B, Devereux RB, Kjeldsen SE, et al : Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995–1003.
Oparil S, Williams D, Chrysant SG, Marbury TC, Neutel J : Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension. J Clin Hypertens (Greenwich) 2001; 3: 283–291, 318.
Smith DH, Dubiel R, Jones M : Use of 24-hour ambulatory blood pressure monitoring to assess antihypertensive efficacy: a comparison of olmesartan medoxomil, losartan potassium, valsartan, and irbesartan. Am J Cardiovasc Drugs 2005; 5: 41–50.
Brunner HR, Arakawa K : Antihypertensive efficacy of olmesartan medoxomil and candesartan cilexetil in achieving 24-hour blood pressure reductions and ambulatory blood pressure goals. Clin Drug Investig 2006; 26: 185–193.
Kario K, Pickering TG, Umeda Y, et al : Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives: a prospective study. Circulation 2003; 107: 1401–1406.
Benson SC, Pershadsingh HA, Ho CI, et al : Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 2004; 43: 993–1002.
Schupp M, Janke J, Clasen R, Unger T, Kintscher U : Angiotensin type 1 receptor blockers induce peroxisome proliferator−activated receptor-gamma activity. Circulation 2004; 109: 2054–2057.
Schupp M, Clemenz M, Gineste R, et al : Molecular characterization of new selective peroxisome proliferator−activated receptor gamma modulators with angiotensin receptor blocking activity. Diabetes 2005; 54: 3442–3452.
Miura Y, Yamamoto N, Tsunekawa S, et al : Replacement of valsartan and candesartan by telmisartan in hypertensive patients with type 2 diabetes: metabolic and antiatherogenic consequences. Diabetes Care 2005; 28: 757–758.
Vitale C, Mercuro G, Castiglioni C, et al : Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome. Cardiovasc Diabetol 2005; 4: 6.
Lacourciere Y, Krzesinski JM, White WB, Davidai G, Schumacher H : Sustained antihypertensive activity of telmisartan compared with valsartan. Blood Press Monit 2004; 9: 203–210.
Inaba M, Noguchi Y, Yamamoto T, et al : Effects of a low dose of indapamide, a diuretic, given daily or every-other-day on blood pressure and metabolic parameters. Hypertens Res 2004; 27: 141–145.
Heart Outcomes Prevention Evaluation Study Investigators : Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355: 253–259.
2003 European Society of Hypertension−European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011–1053.
Clement DL, De Buyzere ML, De Bacquer DA, et al : Prognostic value of ambulatory blood-pressure recordings in patients with treated hypertension. N Engl J Med 2003; 348: 2407–2415.
Neutel J, Smith DH : Evaluation of angiotensin II receptor blockers for 24-hour blood pressure control: meta-analysis of a clinical database. J Clin Hypertens (Greenwich) 2003; 5: 58–63.
Julius S, Kjeldsen SE, Weber M, et al : Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363: 2022–2031.
Fliser D, Buchholz K, Haller H : Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation 2004; 110: 1103–1107.
Link A, Lenz M, Legner D, Bohm M, Nickenig G : Telmisartan inhibits beta2-integrin MAC-1 expression in human T-lymphocytes. J Hypertens 2006; 24: 1891–1898.
Nagel JM, Tietz AB, Goke B, Parhofer KG : The effect of telmisartan on glucose and lipid metabolism in nondiabetic, insulin-resistant subjects. Metabolism 2006; 55: 1149–1154.
Han Y, Runge MS, Brasier AR : Angiotensin II induces interleukin-6 transcription in vascular smooth muscle cells through pleiotropic activation of nuclear factor-kappa B transcription factors. Circ Res 1999; 84: 695–703.
Schieffer B, Schieffer E, Hilfiker-Kleiner D, et al : Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques: potential implications for inflammation and plaque instability. Circulation 2000; 101: 1372–1378.
Picard F, Auwerx J : PPAR(gamma) and glucose homeostasis. Annu Rev Nutr 2002; 22: 167–197.
Staels B, Fruchart JC : Therapeutic roles of peroxisome proliferator−activated receptor agonists. Diabetes 2005; 54: 2460–2470.
Bahadir O, Uzunlulu M, Oguz A, Bahadir MA : Effects of telmisartan and losartan on insulin resistance in hypertensive patients with metabolic syndrome. Hypertens Res 2007; 30: 49–53.
Benndorf RA, Rudolph T, Appel D, et al : Telmisartan improves insulin sensitivity in nondiabetic patients with essential hypertension. Metabolism 2006; 55: 1159–1164.
Usui I, Fujisaka S, Yamazaki K, et al : Telmisartan reduced blood pressure and HOMA-IR with increasing plasma leptin level in hypertensive and type 2 diabetic patients. Diabetes Res Clin Pract 2007; 77: 210–214.
Derosa G, Cicero AF, D'Angelo A, et al : Telmisartan and irbesartan therapy in type 2 diabetic patients treated with rosiglitazone: effects on insulin-resistance, leptin and tumor necrosis factor-α. Hypertens Res 2006; 29: 849–856.
Sugimoto K, Qi NR, Kazdova L, Pravenec M, Ogihara T, Kurtz TW : Telmisartan but not valsartan increases caloric expenditure and protects against weight gain and hepatic steatosis. Hypertension 2006; 47: 1003–1009.
About this article
Cite this article
Nakayama, S., Watada, H., Mita, T. et al. Comparison of Effects of Olmesartan and Telmisartan on Blood Pressure and Metabolic Parameters in Japanese Early-Stage Type-2 Diabetics with Hypertension. Hypertens Res 31, 7–13 (2008). https://doi.org/10.1291/hypres.31.7
- type-2 diabetes
- peroxisome proliferation−activated receptor γ
Effects of azilsartan compared with telmisartan on insulin resistance in patients with essential hypertension and type 2 diabetes mellitus: An open-label, randomized clinical trial
PLOS ONE (2019)
The short‐term effects of angiotensin II receptor blockers on albuminuria and renal function in Korean patients
Basic & Clinical Pharmacology & Toxicology (2019)
Differential effects of candesartan and olmesartan on adipose tissue activity biomarkers in type II diabetic hypertensive patients
Hypertension Research (2010)
Hypertension Research (2010)
Update on therapeutic strategies to increase adiponectin function and secretion in metabolic syndrome
Diabetes, Obesity and Metabolism (2009)